1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Applied Biosciences Corp.

Applied Biosciences Corp.

APPB
Applied Biosciences Corp.US flagOther OTC
0.00
USD
- -
- -
1,365.00Market Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
TTM
Revenue per Share
- -
- -
- -
- -
0.01
0.06
0.06
Basic EPS, GAAP
- -
- -
- -
-0.04
-0.16
-0.22
-0.2
Free Cash Flow per Basic Share
- -
- -
- -
-0.02
-0.04
-0.08
-0.07
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
0.01
- -
-0.04
-0.19
-0.46
-0.59
Tangible Book Value per Share
- -
- -
- -
0.04
0.04
0.11
-0.06
Basic Weighted Avg Shares
213
259
26
12
15
12
14
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
1
1
Operating Margin (%)
- -
- -
- -
-306.35
-755.84
-374.27
-311.94
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
-1
-2
-3
-3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-1,136.36
-1,202.76
-371.87
-324.08
Working Capital
- -
- -
- -
- -
- -
- -
-2
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
2
1
3
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-0.65
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'20
Sep'20
Dec'20
ST Debt
- -
- -
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
14
14
Market Capitalization
85
100
55

Working Capital

FRC

•

in mil. unless spec.
Jun'20
Sep'20
Dec'20
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
2
Payables & Accruals
- -
1
1
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-4,089.55%
389.54%
Free Cash Flow
- -
365.67%
33.68%
Net Income, GAAP
- -
595.01%
10.66%
Sales/Revenue/Turnover
- -
- -
257.91%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
1
2020
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
-0.01
-0.01
-0.02
- -
-0.16
2019
-0.04
-0.01
-0.16
- -
-0.22
2020
-0.03
-0.06
-0.1
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Christopher Michael Bridges
Full Time Employees
25
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
9701 Wilshire Boulevard Beverly Hills CA United States of America 90212
IPO Date
Feb 9, 2016
CIK
0001607549
Website
appliedbiocorp.com
Similar Companies
JBM (Healthcare) Limited (2161.HK)
Leef Brands Inc. (LEEEF)
The United Laboratories International Holdings Limited (3933.HK)
Vifor Pharma AG (VIFN.SW)
Global Roundtable Corporation (GRCU)
Sawai Group Holdings Co., Ltd. (SWGHF)
Business
Applied Biosciences Corp. (APPB) is a vertically integrated biotechnology company focused on the development and commercialization of novel, science-driven synthetic cannabinoid therapeutics and biopharmaceuticals that target the endocannabinoid system to treat a wide range of diseases across multiple therapeutic areas; it also offers high-quality over-the-counter THC-free CBD consumer products, including creams, tinctures, edibles, and confections that promote health and wellbeing, as well as state-of-the-art testing and analytics services for customers in the medical, bioceutical, pet health, recreational, nutraceutical, and media industries. Founded in 2014 and headquartered in Carson City, Nevada, with operational facilities and sourcing in states including California, Colorado, Nevada, and Florida, the company serves markets primarily in the United States and select international regions through exclusive strategic alliances and partnerships aimed at market leadership in the endocannabinoid space. While actively pursuing additional partnerships and growth opportunities, Applied Biosciences maintains its core pipeline advancement without recent public disclosures of major funding rounds, acquisitions, new product launches, or strategic shifts within the last 1-2 years.